Loading clinical trials...
Loading clinical trials...
A Phase Ib/II Study to Evaluate HMBD-001 in Combination With Cetuximab, With or Without Docetaxel in Participants With Advanced Squamous Cell Carcinomas
Conditions
Interventions
HMBD-001
Docetaxel
+1 more
Locations
20
Australia
GenesisCare North Shore
Sydney, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
ICON Cancer Centre South Brisbane
Brisbane, Queensland, Australia
Greenslopes Private Hospital
Greenslopes, Queensland, Australia
Southern Oncology Clinical Research Unit
Adelaide, South Australia, Australia
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia
Start Date
February 5, 2024
Primary Completion Date
December 1, 2027
Completion Date
December 1, 2027
Last Updated
April 15, 2026
NCT05039801
NCT07371234
NCT05214222
NCT06715501
NCT04533750
NCT06342167
Lead Sponsor
Hummingbird Bioscience
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions